Christopher E. Goldring

12.2k total citations · 4 hit papers
124 papers, 7.1k citations indexed

About

Christopher E. Goldring is a scholar working on Molecular Biology, Pharmacology and Hepatology. According to data from OpenAlex, Christopher E. Goldring has authored 124 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Molecular Biology, 35 papers in Pharmacology and 27 papers in Hepatology. Recurrent topics in Christopher E. Goldring's work include Genomics, phytochemicals, and oxidative stress (30 papers), Drug-Induced Hepatotoxicity and Protection (27 papers) and Liver physiology and pathology (20 papers). Christopher E. Goldring is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (30 papers), Drug-Induced Hepatotoxicity and Protection (27 papers) and Liver physiology and pathology (20 papers). Christopher E. Goldring collaborates with scholars based in United Kingdom, Switzerland and United States. Christopher E. Goldring's co-authors include Neil R. Kitteringham, B. Kevin Park, T.M.A. Olayanju, Ian M. Copple, Rosalind E. Jenkins, B. Kevin Park, B. Kevin Park, Daniel J. Antoine, James W. Dear and Joanne Walsh and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Christopher E. Goldring

119 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation

2012 873 citations Christopher E. Goldring et al. profile →
Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease

2016 517 citations Joanne Walsh, Rowena Sison‐Young et al. Scientific Reports profile →
Managing the challenge of chemically reactive metabolites in drug development

2011 338 citations B. Kevin Park, Christopher E. Goldring et al. profile →
Mechanistic Biomarkers Provide Early and Sensitive Detection of Acetaminophen-Induced Acute Liver Injury at First Presentation to Hospital

2013 328 citations Daniel J. Antoine, James W. Dear et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher E. Goldring United Kingdom	43	3.8k	1.5k	1.1k	841	814	124	7.1k
Ramiro Jover Spain	43	1.9k 0.5×	1.8k 1.2×	796 0.7×	1.1k 1.3×	413 0.5×	116	5.4k
Cheng Huang China	51	4.4k 1.2×	632 0.4×	730 0.7×	1.7k 2.0×	1.3k 1.6×	263	8.8k
Sang Geon Kim South Korea	56	5.4k 1.4×	1.5k 1.0×	578 0.5×	1.5k 1.8×	1.1k 1.4×	241	9.4k
María José Gómez‐Lechón Spain	33	1.2k 0.3×	757 0.5×	670 0.6×	973 1.2×	382 0.5×	81	4.8k
Shizhong Zheng China	50	3.5k 0.9×	872 0.6×	1.8k 1.6×	2.6k 3.1×	1.4k 1.7×	184	7.9k
Lina Xu China	48	3.3k 0.9×	845 0.5×	367 0.3×	876 1.0×	745 0.9×	162	6.2k
Yvonne Will United States	37	2.6k 0.7×	1.0k 0.7×	347 0.3×	442 0.5×	321 0.4×	84	5.3k
André Guillouzo France	56	3.4k 0.9×	3.3k 2.1×	2.4k 2.2×	1.2k 1.4×	934 1.1×	192	10.0k
Daniel J. Antoine United Kingdom	37	1.6k 0.4×	1.5k 1.0×	872 0.8×	1.1k 1.4×	672 0.8×	75	5.6k
Anup Ramachandran United States	49	2.3k 0.6×	4.1k 2.7×	2.3k 2.1×	1.7k 2.0×	278 0.3×	136	7.8k

Countries citing papers authored by Christopher E. Goldring

Since Specialization

Citations

This map shows the geographic impact of Christopher E. Goldring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher E. Goldring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher E. Goldring more than expected).

Fields of papers citing papers by Christopher E. Goldring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher E. Goldring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher E. Goldring. The network helps show where Christopher E. Goldring may publish in the future.

Co-authorship network of co-authors of Christopher E. Goldring

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher E. Goldring. A scholar is included among the top collaborators of Christopher E. Goldring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher E. Goldring. Christopher E. Goldring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taylor, Katrina A., R. Ram, Lorna Ewart, et al.. (2025). Perspective: How complex in vitro models are addressing the challenges of predicting drug-induced liver injury. SHILAP Revista de lepidopterología. 5.

Gilbert, Timothy, Laura E. Randle, Robert Jones, et al.. (2024). Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management. European Journal of Surgical Oncology. 51(2). 108352–108352.

Livoti, Lucia A, Rowena Sison‐Young, Ciarán Fisher, et al.. (2024). Limitations of acetaminophen as a reference hepatotoxin for the evaluation of in vitro liver models. Toxicological Sciences. 203(1). 35–40. 1 indexed citations

Gilbert, Timothy, et al.. (2024). The importance of preclinical models in cholangiocarcinoma. European Journal of Surgical Oncology. 51(2). 108304–108304. 2 indexed citations

Gilbert, Timothy, et al.. (2024). Developing a patient-derived model of cholangiocarcinoma using Precision Cut Tissue Slices (PCTS).. European Journal of Surgical Oncology. 50(2). 107758–107758. 1 indexed citations

Jorgensen, Andrea, et al.. (2024). Establishing reference ranges for circulating biomarkers of drug‐induced liver injury in healthy human volunteers ¹. British Journal of Clinical Pharmacology. 91(5). 1361–1369.

Qin, Meng, Yuehua Zhou, Dandan Song, et al.. (2024). Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies. Applied Biochemistry and Biotechnology. 197(4). 2180–2196.

Haldenby, Sam, Anna Fowler, Katie Bullock, et al.. (2023). Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Scientific Reports. 13(1). 6681–6681. 5 indexed citations

Pridgeon, Chris S., Shiva S. Forootan, Fang Zhang, et al.. (2023). In Vivo Tumorigenicity of the 20q11.21 Amplicon in an Engraftment Model of hPSCs and Differentiated Liver Cells. PubMed. 19(1). 3–13. 1 indexed citations

10.

Aljasir, Mohammad Abdullah, et al.. (2023). VEGF Stimulates Activation of ERK5 in the Absence of C-Terminal Phosphorylation Preventing Nuclear Localization and Facilitating AKT Activation in Endothelial Cells. Cells. 12(6). 967–967. 2 indexed citations

11.

Jenkins, Rosalind E., et al.. (2021). Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification. Archives of Toxicology. 95(7). 2413–2430. 2 indexed citations

12.

Greco, Karin Vicente, et al.. (2018). Application of porcine gastrointestinal organoid units as a potential in vitro tool for drug discovery and development. Journal of Applied Toxicology. 39(1). 4–15. 24 indexed citations

13.

Sutton, Paul, Puthen V. Jithesh, Rosalind E. Jenkins, et al.. (2018). Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response. Journal of Proteomics. 179. 53–60. 19 indexed citations

14.

Shelton, Luke M., Adam Lister, Joanne Walsh, et al.. (2015). Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. Kidney International. 88(6). 1261–1273. 44 indexed citations

15.

Walsh, Joanne, Laura E. Randle, Ina Schuppe‐Koistinen, et al.. (2015). Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome. Scientific Reports. 5(1). 16423–16423. 25 indexed citations

16.

Vliegenthart, A. D. Bastiaan, Philip Starkey Lewis, Carl S. Tucker, et al.. (2014). Retro-Orbital Blood Acquisition Facilitates Circulating microRNA Measurement in Zebrafish with Paracetamol Hepatotoxicity. Zebrafish. 11(3). 219–226. 25 indexed citations

17.

Antoine, Daniel J., James W. Dear, Philip Starkey Lewis, et al.. (2013). Mechanistic Biomarkers Provide Early and Sensitive Detection of Acetaminophen-Induced Acute Liver Injury at First Presentation to Hospital. Hepatology. 58(2). 777–787. 328 indexed citations breakdown →

18.

Lewis, Philip Starkey, James W. Dear, Vivien Platt, et al.. (2011). Identification of endogenous normalizers for serum MicroRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology. 55(5). 1642–1643. 2 indexed citations

19.

Baxter, M., Cliff Rowe, Jane Alder, et al.. (2010). Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Research. 5(1). 4–22. 48 indexed citations

20.

Randle, Laura E., et al.. (2007). Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice. Toxicology. 243(3). 249–260. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact